Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like BioTime Expands OpRegen Clinical Trial In Dry-AMD With Opening Of First U.S. Sites March 12, 2017 <b>Detact Diagnostics</b> Receives ???2.1 Million Investment From NOM Finance April 18, 2017 Syndax To Announce First Quarter 2017 Financial Results And Host Conference Call And Webcast On May 8, 2017 April 30, 2017
Syndax To Announce First Quarter 2017 Financial Results And Host Conference Call And Webcast On May 8, 2017 April 30, 2017
